scholarly journals Prognostic Factors for Patients with Esophageal Cancer Receiving Definitive Radiotherapy Alone: A Retrospective Analysis

2021 ◽  
Vol Volume 13 ◽  
pp. 3229-3234
Author(s):  
Nan Jiang ◽  
Xiao-Lin Ge ◽  
Zhao-Yue Zhang ◽  
Jia Liu ◽  
Pei-Pei Wang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Definitive Radiotherapy ◽  
Radiotherapy Alone

scholarly journals Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy

2015 ◽  
Vol 56 (4) ◽  
pp. 742-749 ◽  
Author(s):  
Matthias F. Haefner ◽  
Kristin Lang ◽  
David Krug ◽  
Stefan A. Koerber ◽  
Lorenz Uhlmann ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factors ◽  
Definitive Radiotherapy ◽  
Patterns Of Recurrence

scholarly journals Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer

2019 ◽  
Vol 66 (1.2) ◽  
pp. 99-105 ◽  
Author(s):  
Chisato Tonoiso ◽  
Hitoshi Ikushima ◽  
Akiko Kubo ◽  
Takashi Kawanaka ◽  
Shunsuke Funatani ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Definitive Radiotherapy

scholarly journals Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy

2019 ◽  
Author(s):  
Xin-xin Du ◽  
Rong Yu ◽  
Zhen-fei Wang ◽  
De-cheng Du ◽  
Qiao-yun Liu ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Prognostic Factor ◽  
Clinical Stage ◽  
Independent Prognostic Factor ◽  
Tumor Control ◽  
Cervical Esophageal Cancer ◽  
Free Survival ◽  
Definitive Radiotherapy

Cervical esophageal cancer (CEC) is uncommon, accounting for less than 5% of all esophageal cancers. The management of CEC is controversial. This study investigated treatment outcomes and prognostic factors of survival in CEC patients undergoing definitive radiotherapy or concurrent chemoradiotherapy (CCRT). Ninety-one CEC patients were treated by intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3DCRT) between July 2007 and September 2017. The mean prescription dose was 64 Gy (range 54-70 Gy) delivered as 1.8-2.2 Gy per fraction per day, 5 days a week. Out of 91 patients, 34 received concurrent cisplatin-based chemotherapy (CT) including 18 patients who also received neoadjuvant CT. Overall survival (OS), locoregional failure-free survival (LRFFS), and progression-free survival (PFS) were estimated by the Kaplan–Meier method. Prognostic factors of survival were determined in univariate (log-rank test) and multivariate (Cox proportional hazard model) analysis. Treatment-related toxicity was also assessed. Median follow-up time for all patients was 19 months. Two-year OS, LRFFS and PFS of all patients were 58.2%, 52.5% and 48.1%, respectively. Clinical stage was an independent prognostic factor for OS (HR = 2.35, 95% CI: 1.03-5.37, p = 0.042), LRFFS (HR = 3.84, 95% CI: 1.38-10.69, p = 0.011), and PFS (HR = 2.68, 95% CI: 1.11-6.45, p = 0.028). Hoarseness was an independent prognostic factor for OS (HR = 2.10, 95% CI: 1.05-4.19, p = 0.036). CCRT was independently associated with better LRFFS (HR = 0.33, 95% CI: 0.14-0.79, p = 0.012). 3DCRT and IMRT with concurrent CT is well-tolerated and may improve local tumor control in CEC patients. Advanced clinical stage and hoarseness are adverse prognostic factors for OS, LRFFS, and PFS in CEC.

scholarly journals P1-9 Retrospective analysis of the efficacy and safety of FOLFOX in patients with esophageal cancer

2021 ◽  
Vol 32 ◽  
pp. S329
Author(s):  
Koshi Sukeno ◽  
Akira Tsunoda ◽  
Yasutaka Tono ◽  
Hiroyasu Oda ◽  
Mikiya Ishihara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Retrospective Analysis ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document